ARVN
Price
$6.19
Change
-$0.18 (-2.83%)
Updated
Apr 8, 04:59 PM (EDT)
Capitalization
438.08M
28 days until earnings call
GMAB
Price
$17.99
Change
-$0.20 (-1.10%)
Updated
Apr 8, 04:59 PM (EDT)
Capitalization
11.52B
30 days until earnings call
Ad is loading...

ARVN vs GMAB

Header iconARVN vs GMAB Comparison
Open Charts ARVN vs GMABBanner chart's image
Arvinas
Price$6.19
Change-$0.18 (-2.83%)
Volume$43.94K
Capitalization438.08M
Genmab A/S ADS
Price$17.99
Change-$0.20 (-1.10%)
Volume$19.57K
Capitalization11.52B
ARVN vs GMAB Comparison Chart
Loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARVN vs. GMAB commentary
Apr 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a StrongBuy and GMAB is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 09, 2025
Stock price -- (ARVN: $6.37 vs. GMAB: $18.19)
Brand notoriety: ARVN and GMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARVN: 141% vs. GMAB: 214%
Market capitalization -- ARVN: $438.08M vs. GMAB: $11.52B
ARVN [@Biotechnology] is valued at $438.08M. GMAB’s [@Biotechnology] market capitalization is $11.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARVN’s FA Score shows that 1 FA rating(s) are green whileGMAB’s FA Score has 0 green FA rating(s).

  • ARVN’s FA Score: 1 green, 4 red.
  • GMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, ARVN is a better buy in the long-term than GMAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARVN’s TA Score shows that 5 TA indicator(s) are bullish while GMAB’s TA Score has 4 bullish TA indicator(s).

  • ARVN’s TA Score: 5 bullish, 4 bearish.
  • GMAB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARVN is a better buy in the short-term than GMAB.

Price Growth

ARVN (@Biotechnology) experienced а -9.26% price change this week, while GMAB (@Biotechnology) price change was -7.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.88%. For the same industry, the average monthly price growth was -20.27%, and the average quarterly price growth was -19.68%.

Reported Earning Dates

ARVN is expected to report earnings on Jul 31, 2025.

GMAB is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-9.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GMAB($11.5B) has a higher market cap than ARVN($438M). GMAB YTD gains are higher at: -12.841 vs. ARVN (-66.771). GMAB has higher annual earnings (EBITDA): 9.7B vs. ARVN (-243.6M). GMAB has more cash in the bank: 21.1B vs. ARVN (1.04B). ARVN has less debt than GMAB: ARVN (9.7M) vs GMAB (1.03B). GMAB has higher revenues than ARVN: GMAB (21.5B) vs ARVN (263M).
ARVNGMABARVN / GMAB
Capitalization438M11.5B4%
EBITDA-243.6M9.7B-3%
Gain YTD-66.771-12.841520%
P/E RatioN/A10.13-
Revenue263M21.5B1%
Total Cash1.04B21.1B5%
Total Debt9.7M1.03B1%
FUNDAMENTALS RATINGS
ARVN vs GMAB: Fundamental Ratings
ARVN
GMAB
OUTLOOK RATING
1..100
5653
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
62
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4440
PRICE GROWTH RATING
1..100
9884
P/E GROWTH RATING
1..100
10097
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARVN's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for GMAB (62) in the null industry. This means that ARVN’s stock grew somewhat faster than GMAB’s over the last 12 months.

ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GMAB (100) in the null industry. This means that ARVN’s stock grew similarly to GMAB’s over the last 12 months.

GMAB's SMR Rating (40) in the null industry is in the same range as ARVN (44) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

GMAB's Price Growth Rating (84) in the null industry is in the same range as ARVN (98) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

GMAB's P/E Growth Rating (97) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that GMAB’s stock grew similarly to ARVN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARVNGMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
51%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
64%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 7 days ago
80%
Bullish Trend 6 days ago
64%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
67%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
54%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ACECX9.03N/A
N/A
American Century Emerging Markets C
MGNDX39.38N/A
N/A
Praxis Growth Index A
TBCUX14.34N/A
N/A
Tweedy, Browne Intl Val II - Ccy UnH
MSJIX14.55N/A
N/A
Morgan Stanley Global Endurance I
HSWCX16.56-0.38
-2.24%
Hartford Schroders International Stk C

ARVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-2.90%
AXON - ARVN
46%
Loosely correlated
+1.09%
VCYT - ARVN
46%
Loosely correlated
+2.00%
IDYA - ARVN
42%
Loosely correlated
+2.92%
ERAS - ARVN
40%
Loosely correlated
+5.60%
ATXS - ARVN
40%
Loosely correlated
-3.33%
More

GMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.09%
GNMSF - GMAB
58%
Loosely correlated
-2.58%
AXON - GMAB
47%
Loosely correlated
+1.09%
VCYT - GMAB
35%
Loosely correlated
+2.00%
TECH - GMAB
34%
Loosely correlated
+1.14%
ARVN - GMAB
33%
Loosely correlated
-2.90%
More